Single User License
INR 136060
Site License
INR 272120
Corporate User License
INR 408180

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Angina (Angina Pectoris)-Pipeline Review, H1 2015

Angina (Angina Pectoris)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Angina (Angina Pectoris)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Angina (Angina Pectoris)-Pipeline Review, H1 2015', provides an overview of the Angina (Angina Pectoris)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Angina (Angina Pectoris), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Angina (Angina Pectoris) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Angina (Angina Pectoris)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Angina (Angina Pectoris) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Angina (Angina Pectoris) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Angina (Angina Pectoris) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Angina (Angina Pectoris)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Angina (Angina Pectoris) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Angina (Angina Pectoris) Overview 9

Therapeutics Development 10

Pipeline Products for Angina (Angina Pectoris)-Overview 10

Pipeline Products for Angina (Angina Pectoris)-Comparative Analysis 11

Angina (Angina Pectoris)-Therapeutics under Development by Companies 12

Angina (Angina Pectoris)-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Angina (Angina Pectoris)-Products under Development by Companies 17

Angina (Angina Pectoris)-Companies Involved in Therapeutics Development 19

Bayer AG 19

Cardiolynx AG 20

CJ CheilJedang Corp. 21

Gilead Sciences, Inc. 22

Hemostemix Ltd 23

Jiangsu Hengrui Medicine Co., Ltd. 24

Juventas Therapeutics, Inc. 25

Kuhnil Pharmaceutical Co., Ltd. 26

Lacer, S.A. 27

Lee's Pharmaceutical Holdings Limited 28

LegoChem Biosciences, Inc 29

Milestone Pharmaceuticals, Inc. 30

Taxus Cardium Pharmaceuticals Group Inc. 31

ViroMed Co., Ltd. 32

Angina (Angina Pectoris)-Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Target 34

Assessment by Mechanism of Action 36

Assessment by Route of Administration 38

Assessment by Molecule Type 40

Drug Profiles 42

ACP-01-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

aladorian sodium-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

alferminogene tadenovec-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

BAY-606583-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

CJ-30059-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

CLC-1201-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

CLC-1280-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

GS-6615-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

ivabradine hydrochloride SR-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

JVS-100-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

KI-1007-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

LA-419-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

LA-8045-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

MSP-2017-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecule to Activate Soluble Guanylate Cyclase for Angina Pectoris-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecules to Antagonize Ryanodine Receptor 2 for Ventricular Arrhythmia-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

VM-202-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

ZK-001-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Angina (Angina Pectoris)-Recent Pipeline Updates 68

Angina (Angina Pectoris)-Dormant Projects 76

Angina (Angina Pectoris)-Discontinued Products 79

Angina (Angina Pectoris)-Product Development Milestones 80

Featured News & Press Releases 80

Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 80

Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' 82

May 09, 2014: Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 83

May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 84

Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 86

Sep 20, 2012: Cardiolynx Receives Patent For Improved Angina Pectoris Drug CLC-1280 87

Jul 07, 2011: Phase Two Study Suggests Use Of Adult Autologous Stem Cells May Improve Cardiac Function In Angina Patients 88

Apr 18, 2011: Lee's Pharma Completes Phase I Study Of Anti-Platelet Drug Declotana 89

Nov 03, 2010: Cardium Awarded Grant Under QTDP Program 89

Oct 23, 2007: Announcement of supplemental approval of indication of Sigmart Injection, a treatment drug for unstable angina pectoris 90

Appendix 91

Methodology 91

Coverage 91

Secondary Research 91

Primary Research 91

Expert Panel Validation 91

Contact Us 91

Disclaimer 92

List of Tables

Number of Products under Development for Angina (Angina Pectoris), H1 2015 10

Number of Products under Development for Angina (Angina Pectoris)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Angina (Angina Pectoris)-Pipeline by Bayer AG, H1 2015 19

Angina (Angina Pectoris)-Pipeline by Cardiolynx AG, H1 2015 20

Angina (Angina Pectoris)-Pipeline by CJ CheilJedang Corp., H1 2015 21

Angina (Angina Pectoris)-Pipeline by Gilead Sciences, Inc., H1 2015 22

Angina (Angina Pectoris)-Pipeline by Hemostemix Ltd, H1 2015 23

Angina (Angina Pectoris)-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 24

Angina (Angina Pectoris)-Pipeline by Juventas Therapeutics, Inc., H1 2015 25

Angina (Angina Pectoris)-Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2015 26

Angina (Angina Pectoris)-Pipeline by Lacer, S.A., H1 2015 27

Angina (Angina Pectoris)-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 28

Angina (Angina Pectoris)-Pipeline by LegoChem Biosciences, Inc, H1 2015 29

Angina (Angina Pectoris)-Pipeline by Milestone Pharmaceuticals, Inc., H1 2015 30

Angina (Angina Pectoris)-Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H1 2015 31

Angina (Angina Pectoris)-Pipeline by ViroMed Co., Ltd., H1 2015 32

Assessment by Monotherapy Products, H1 2015 33

Number of Products by Stage and Target, H1 2015 35

Number of Products by Stage and Mechanism of Action, H1 2015 37

Number of Products by Stage and Route of Administration, H1 2015 39

Number of Products by Stage and Molecule Type, H1 2015 41

Angina (Angina Pectoris) Therapeutics-Recent Pipeline Updates, H1 2015 68

Angina (Angina Pectoris)-Dormant Projects, H1 2015 76

Angina (Angina Pectoris)-Dormant Projects (Contd..1), H1 2015 77

Angina (Angina Pectoris)-Dormant Projects (Contd..2), H1 2015 78

Angina (Angina Pectoris)-Discontinued Products, H1 2015 79

List of Figures

Number of Products under Development for Angina (Angina Pectoris), H1 2015 10

Number of Products under Development for Angina (Angina Pectoris)-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 33

Number of Products by Top 10 Targets, H1 2015 34

Number of Products by Stage and Top 10 Targets, H1 2015 34

Number of Products by Top 10 Mechanism of Actions, H1 2015 36

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 37

Number of Products by Top 10 Routes of Administration, H1 2015 38

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 39

Number of Products by Top 10 Molecule Types, H1 2015 40

Number of Products by Stage and Top 10 Molecule Types, H1 2015 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Bayer AG

Cardiolynx AG

CJ CheilJedang Corp.

Gilead Sciences, Inc.

Hemostemix Ltd

Jiangsu Hengrui Medicine Co., Ltd.

Juventas Therapeutics, Inc.

Kuhnil Pharmaceutical Co., Ltd.

Lacer, S.A.

Lee's Pharmaceutical Holdings Limited

LegoChem Biosciences, Inc

Milestone Pharmaceuticals, Inc.

Taxus Cardium Pharmaceuticals Group Inc.

ViroMed Co., Ltd.

Angina (Angina Pectoris) Therapeutic Products under Development, Key Players in Angina (Angina Pectoris) Therapeutics, Angina (Angina Pectoris) Pipeline Overview, Angina (Angina Pectoris) Pipeline, Angina (Angina Pectoris) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com